CN106511915B - A kind of compound traditional Chinese medicine composite is inhibiting the application in cutaneous melanoma Lung metastases drug - Google Patents
A kind of compound traditional Chinese medicine composite is inhibiting the application in cutaneous melanoma Lung metastases drug Download PDFInfo
- Publication number
- CN106511915B CN106511915B CN201710029836.8A CN201710029836A CN106511915B CN 106511915 B CN106511915 B CN 106511915B CN 201710029836 A CN201710029836 A CN 201710029836A CN 106511915 B CN106511915 B CN 106511915B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- compound traditional
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 103
- 150000001875 compounds Chemical class 0.000 title claims abstract description 50
- 239000002131 composite material Substances 0.000 title claims abstract description 29
- 206010027458 Metastases to lung Diseases 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- 208000030381 cutaneous melanoma Diseases 0.000 title claims abstract description 8
- 201000003708 skin melanoma Diseases 0.000 title claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 title description 7
- 241000756943 Codonopsis Species 0.000 claims abstract description 13
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 13
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 13
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 13
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 13
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 13
- 244000197580 Poria cocos Species 0.000 claims abstract description 13
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 13
- 229940107666 astragalus root Drugs 0.000 claims abstract description 13
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 12
- 240000008488 Thlaspi arvense Species 0.000 claims abstract description 12
- 235000008214 Thlaspi arvense Nutrition 0.000 claims abstract description 12
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 12
- 201000001441 melanoma Diseases 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 235000008504 concentrate Nutrition 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 241000497005 Ixophorus unisetus Species 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 235000019441 ethanol Nutrition 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 238000002386 leaching Methods 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000148137 Patrinia villosa Species 0.000 description 1
- 235000019109 Patrinia villosa Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of compound traditional Chinese medicine composites to inhibit the application in cutaneous melanoma Lung metastases drug, wherein the compound traditional Chinese medicine composite includes the component of following parts by weight: 15~30 parts of astragalus root, fry 15~30 parts of Radix Codonopsis, 10~20 parts of rhizoma atractylodis macrocephalae, 15~30 parts of Poria cocos, 15~30 parts of Chinese yam, 5~10 parts of radix glycyrrhizae preparata, 10~20 parts of dark plum, 10~20 parts of trigone, 10~20 parts of curcuma zedoary of toast, 15~30 parts of hairyvein agrimony, 15~30 parts of field pennycress.Compound composite medicament of the invention has in the case where not reducing immunity of organisms, significantly inhibits cutaneous melanoma Lung metastases, while the production of the medicine is cheap, application easy to spread.
Description
Technical field
The present invention relates to traditional Chinese medicine technologies, and in particular to a kind of compound traditional Chinese medicine composite is inhibiting cutaneous melanoma Lung metastases
Application in drug.
Background technique
Melanoma is the most important tumor type of dermatology, originates from the melanocyte at epidermal-dermal junction,
It can also be from positions such as mucous membrane or ocular choroids.This kind of tumour is the highest one kind of relatively rare but grade malignancy, in institute
Its disease incidence is about 0.1/10 ten thousand people in You Fei developed country, but its lethality accounts for 97%, is easier to DISTANT METASTASES IN occur, especially
Lung metastases, therefore should attract great attention.
As the overall incidence of compatriots' living-pattern preservation, the pollution of environment, tumour increases year by year.Tumor patient mesh
It is preceding in addition to operation other than, many First-line chemotherapies are still the Cocktail treatment based on cytotoxic drug.Chemotherapeutic
Although also having certain lethal effect for intracorporal normal cell using Partial tumors cell has been eliminated.Clinically patient
The case where using will appear hypoimmunity after chemotherapeutic, zoopery show the experiment mice after 5 FU 5 fluorouracil intervention,
Weight, spleen index, T lymphocyte proliferation activity, CD4/CD8 ratio are substantially reduced, oligoleukocythemia, atrophy of immune organ, huge
Phagocyte phagocytic function reduces and the decline of NK cell activity.
The patient of melanoma is sought to reduce its DISTANT METASTASES IN how on the basis of not lowering its immunity
The treatment method of supplement and substitution is just at the task of top priority, and traditional Chinese medicine treatment shows its unique advantage in this respect.Mesh
Before have a large amount of clinical and Basic Experiment Study show traditional Chinese medicine in terms of treat malignant tumour with good curative effect, in addition to
Outside the effect for directly killing tumour, traditional Chinese medicine can also play indirect effect, it being reached by strengthening vital QI to eliminate pathogenic factors improves disease
Shape is improved the quality of living, and is reduced transfer and is extended the purpose of life cycle.
Summary of the invention
Technical problem to be solved by the invention is to provide a kind of compound traditional Chinese medicine composites to inhibit cutaneous melanoma lung
Application in diversion medicaments.
In order to solve the above technical problems, The technical solution adopted by the invention is as follows:
A kind of compound traditional Chinese medicine composite is inhibiting the application in cutaneous melanoma Lung metastases drug,
Wherein, the compound traditional Chinese medicine composite includes the component of following parts by weight: 15~30 parts of astragalus root, frying Radix Codonopsis
15~30 parts, 10~20 parts of rhizoma atractylodis macrocephalae, 15~30 parts of Poria cocos, 15~30 parts of Chinese yam, 5~10 parts of radix glycyrrhizae preparata, process dark plum 10~20
Part, 10~20 parts of trigone, 10~20 parts of curcuma zedoary, 15~30 parts of hairyvein agrimony, 15~30 parts of field pennycress.
Wherein, the compound traditional Chinese medicine composite preferably includes the component of following parts by weight:
15~20 parts of astragalus root, 15~20 parts of Radix Codonopsis of stir-fry, 10~15 parts of rhizoma atractylodis macrocephalae, 15~20 parts of Poria cocos, Chinese yam 15~30
Part, 5~10 parts of radix glycyrrhizae preparata, 10~15 parts of dark plum of toast, 10~15 parts of trigone, 10~15 parts of curcuma zedoary, 20~30 parts of hairyvein agrimony, Patrinia scaniosaefolia
20~30 parts of grass.
Wherein, the compound traditional Chinese medicine composite, dosage form are decoction, syrup, mixture, granule, tablet or capsule
Agent.
Wherein, the compound traditional Chinese medicine composite is prepared as follows to obtain: by the Chinese medicine astragalus root of formula ratio, frying
Radix Codonopsis, rhizoma atractylodis macrocephalae, Poria cocos, Chinese yam, radix glycyrrhizae preparata, toast dark plum, trigone, curcuma zedoary, hairyvein agrimony and field pennycress add water to cook to obtain the final product.
Wherein, it decocts every time, the weight of the water of addition is 5~20 times of Chinese medicine total weight；The number of decoction is 1~3
Secondary, each decocting time is 1~3 hour.
Decocting liquid is concentrated after can also adding water to cook for the preparation method of above-mentioned compound traditional Chinese medicine composite to obtain the final product.
Wherein, the concentration, method one are as follows: decocting liquid is concentrated into 60 DEG C of relative densities 1.05~1.15.
Wherein, the concentration, method two are as follows: decocting liquid is concentrated into 60 DEG C of relative densities 1.05~1.15, then plus ethyl alcohol
It is extracted to alcohol content up to 60~90%, after separation of solid and liquid, takes supernatant, recycle ethyl alcohol in supernatant to being concentrated to the greatest extent
Liquid.
The preparation method of above-mentioned compound medicine, is added or is added without sucrose into concentrate, sterilizing be made syrup or
Decoction；Or, dextrin, Steviosin are added into concentrate, tablet, capsule or granule is made.
Wherein, the compound traditional Chinese medicine composite is by inhibiting melanoma Lung metastases so as to improve the prognosis of disease.
Wherein, the compound traditional Chinese medicine composite can not lower immune cell number while reaching therapeutic effect
Amount.
Compound composite medicament provided by the present invention, the sweet temperature of astragalus root in side, arrogates to oneself air making-up and spleen enlivening, yang invigorating；Fry Radix Codonopsis
Gan Ping arrogates to oneself gas, the nourishing generate fluid of tonifying spleen and stomach, and two medicines share, and it is altogether monarch drug in a prescription that the function of QI invigorating tonifying spleen, which writes,.Rhizoma atractylodis macrocephalae air making-up and spleen enlivening is dry
The benefits of wet, Poria cocos invigorating spleen for diuresis excreting dampness, Chinese yam QI invigorating tonifying spleen yin-nourishing, three medicines associate with, dehumidifying fortune spleen is evident, and temper is filled, have dampness elimination it
Power, it is wet it is turbid go, increase the function of invigorating the spleen, be altogether ministerial drug, play the function of excreting dampness of replenishing qi to invigorate the spleen.Trigone, curcuma zedoary, bitter is violent, arrogates to oneself the heavily fortified point that disappears
Open the stasis of blood, with it in tonic, can both disappear hemostasis is slow, and borrow the power of its circulation, row tonic it is stagnant；The pungent scattered row of field pennycress is stagnant, arrogates to oneself
The carbuncle that disappears apocenosis, the blood-breaking row stasis of blood；Astringing to arrest bleeding, removing toxic substances stop dysentery are arrogated to oneself in the convergence of hairyvein agrimony puckery；It is sour and puckery to process dark plum, arrogates to oneself puckery intestines and stops
It rushes down, analgesic of promoting the production of body fluid, five medicines are adjutant row dissipating blood stasis with potent drugs, hold back the effect of yin removing toxic substances altogether.Radix glycyrrhizae preparata Gan Pingwei makes medicine, invigorate the spleen and benefit qi,
Clearing heat and detoxicating, coordinating the drug actions of a prescription.Therefore all medicines share, its righting tonifying Qi is taken, dissipating blood stasis with potent drugs holds back the effect of yin detoxifies.
According to an embodiment of the invention, using C57BL/6 mouse for experiment, can be lowered using this compound composite medicament black
The Lung metastases degree of melanoma model mice, meets the expection of Chinese medicine " strengthening vital QI to eliminate pathogenic factors ".
The utility model has the advantages that compared with prior art, compound composite medicament of the invention, which has, is not lowering immunity of organisms
In the case of, the curative effect of the significant Lung metastases degree for lowering melanoma, while the production of the medicine is cheap, it is easy to spread to answer
With.
Detailed description of the invention
Fig. 1: the Lung metastases situation after melanoma tumor model mouse Chinese medicine intervention compares.
Upper row: the lung of negative control group mouse；Lower row: the lung of Chinese medicine compound prescription group mouse.Black is to be transferred to lung in figure
Melanoma, white are lung tissue.It can be seen that the lung of control group almost all black, and the lung of Chinese medicine group still has white to deposit
?.
Specific embodiment
The present invention is described further combined with specific embodiments below.It, can be more preferable geographical according to following embodiments
The solution present invention.However, as it will be easily appreciated by one skilled in the art that content described in embodiment is merely to illustrate the present invention,
Without the present invention described in detail in claims should will not be limited.
Embodiment 1
A kind of compound composite medicament lowering melanoma Lung metastases, is grouped as by each group of following parts by weight:
15 parts of astragalus root, 15 parts of Radix Codonopsis are fried, 10 parts of rhizoma atractylodis macrocephalae, 15 parts of Poria cocos, 15 parts of Chinese yam, 5 parts of radix glycyrrhizae preparata, processs dark plum 10
Part, 10 parts of trigone, 10 parts of curcuma zedoary, 30 parts of hairyvein agrimony, 30 parts of field pennycress, totally 11 taste medicine.
In prescription ratio, the above 11 taste prepared slices of Chinese crude drugs are weighed, add the water of 10 times of bulk pharmaceutical chemicals total weight amounts, decocts and extracts 3 times,
1 hour every time.Collecting decoction, as decoction.
Resulting decoction is concentrated into relative density 1.10 (60 DEG C of surveys), adds ethyl alcohol to alcohol content up to 60%, stands 12 hours
More than.Leaching supernatant, recycling ethyl alcohol are concentrated into relative density about 1.10 (60 DEG C survey) to the greatest extent.Simple syrup is added, and adds and steams
Distilled water to the suitable medicine materical crude slice 1g of every mL, filtering, sterilizes to get compound medicine syrup at packing.
Embodiment 2
A kind of compound composite medicament lowering melanoma Lung metastases, is grouped as by each group of following parts by weight:
15 parts of astragalus root, 30 parts of Radix Codonopsis are fried, 10 parts of rhizoma atractylodis macrocephalae, 20 parts of Poria cocos, 15 parts of Chinese yam, 5 parts of radix glycyrrhizae preparata, processs dark plum 10
Part, 15 parts of trigone, 15 parts of curcuma zedoary, 30 parts of hairyvein agrimony, 30 parts of field pennycress, totally 11 taste medicine.
In prescription ratio, the above 11 taste prepared slices of Chinese crude drugs are weighed, add the water of 20 times of bulk pharmaceutical chemicals total weight amounts, decocts and extracts 3 times,
1 hour every time.Collecting decoction is concentrated into relative density 1.08 (60 DEG C of surveys), adds ethyl alcohol to alcohol content up to 60%, stand 24 hours
More than, leaching supernatant, recycling ethyl alcohol is concentrated into relative density about 1.08 (60 DEG C survey) to the greatest extent.Add distilled water to every mL phase
It as medicine materical crude slice 1g, mixes, filters, packing sterilizes to get compound medicine mixture.
Embodiment 3
A kind of compound composite medicament lowering melanoma Lung metastases, is grouped as by each group of following parts by weight:
20 parts of astragalus root, 20 parts of Radix Codonopsis are fried, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of Poria cocos, 15 parts of Chinese yam, 10 parts of radix glycyrrhizae preparata, processs dark plum
15 parts, 10 parts of trigone, 10 parts of curcuma zedoary, 15 parts of hairyvein agrimony, 15 parts of field pennycress, totally 11 taste medicine.
In prescription ratio, the above 11 taste prepared slices of Chinese crude drugs are weighed, add the water of 5 times of bulk pharmaceutical chemicals total weight amounts, decocts and extracts 3 times,
1 hour every time.Collecting decoction is concentrated into relative density 1.10 (60 DEG C of surveys), adds ethyl alcohol to alcohol content up to 60%, stand 24 hours
More than, leaching supernatant, recycling ethyl alcohol is concentrated into relative density about 1.33 (60 DEG C survey) to the greatest extent.Appropriate dextrin, stevia rebaudianum is added
Glycosides is pelletized, dry, and whole grain dispenses to get compound medicine granule.
Embodiment 4
A kind of compound composite medicament lowering melanoma Lung metastases, is grouped as by each group of following parts by weight:
15 parts of astragalus root, 15 parts of Radix Codonopsis are fried, 10 parts of rhizoma atractylodis macrocephalae, 15 parts of Poria cocos, 15 parts of Chinese yam, 5 parts of radix glycyrrhizae preparata, processs dark plum 10
Part, 10 parts of trigone, 10 parts of curcuma zedoary, 20 parts of hairyvein agrimony, 20 parts of field pennycress, totally 11 taste medicine.
In prescription ratio, the above 11 taste prepared slices of Chinese crude drugs are weighed, add the water of 10 times of bulk pharmaceutical chemicals total weight amounts, decocts and extracts 3 times,
1 hour every time.Collecting decoction is concentrated into relative density 1.09 (60 DEG C of surveys), adds ethyl alcohol to alcohol content up to 60%, stand 24 hours
More than, leaching supernatant, recycling ethyl alcohol is concentrated into relative density about 1.35 (60 DEG C survey) to the greatest extent.Appropriate amount of starch, system is added
Grain, dry, whole grain, tabletting, coating dispense to get compound medicine tablet.
Embodiment 5
A kind of compound composite medicament lowering melanoma Lung metastases, is grouped as by each group of following parts by weight:
15 parts of astragalus root, 15 parts of Radix Codonopsis are fried, 10 parts of rhizoma atractylodis macrocephalae, 15 parts of Poria cocos, 15 parts of Chinese yam, 5 parts of radix glycyrrhizae preparata, processs dark plum 10
Part, 10 parts of trigone, 10 parts of curcuma zedoary, 30 parts of hairyvein agrimony, 30 parts of field pennycress, totally 11 taste medicine.
In prescription ratio, the above 11 taste prepared slices of Chinese crude drugs are weighed, add the water of 10 times of bulk pharmaceutical chemicals total weight amounts, decocts and extracts 2 times,
1 hour every time.Collecting decoction is concentrated into relative density 1.12 (60 DEG C of surveys), adds ethyl alcohol to alcohol content up to 60%, stand 24 hours
More than, leaching supernatant, recycling ethyl alcohol is concentrated into relative density about 1.32 (60 DEG C survey) to the greatest extent.Appropriate amount of starch, system is added
Grain, dry, whole grain is encapsulated, dispenses to get compound medicine capsule.
The experimental study of Chinese medicine compound prescription attenuating melanoma Lung metastases: the compound medicine of optional above-described embodiment 1-5 preparation
Prescription decoction is made, carry out the animal experiment of traditional Chinese compound medicine.
Embodiment 6
By taking typical 1 prescription of embodiment as an example, it is illustrated, other embodiments effect is suitable, specific as follows:
Experimental animal: SPF grades C57BL/6 mouse 16, half male and half female, 15~19g of weight must purchased from the western Poole-in Shanghai
Triumphant experimental animal Co., Ltd, quality certification number: SCXK (Shanghai) 2013-0016.
Experimental drug: the decoction of preparation 1 prescription of embodiment is concentrated into and is equivalent to crude drug concentration 6g/mL, this is compound medicine
Object.
Experimental animal grouping: 16 mouse are randomly divided into negative control group (physiological saline group) 8 and Chinese medicine compound prescription is controlled
Treatment group 8.Every equal tail vein injection 3*105A B16F10 mouse melanin tumor cell, the injection same day start groups of animals
Give corresponding pharmaceutical intervention.
Medication: negative control group gavages physiological saline 0.2mL/20g weight daily, and compound of Chinese herbal medicine group fills daily
Take traditional Chinese medicine compound (embodiment 1) 0.2mL/20g weight, it is above one time a day, continuous 24 days.2 hours after the last administration, take off neck
Vertebra puts to death animal, weighs, draws materials, and specific drug composition and administration mode are shown in Table 1.
1 drug of table composition and administration mode
Experimental result:
1) ordinary circumstance: situations such as observing mouse spirit, activity, diet, urine, excrement after administration daily does not find
Abnormal, eye, ear, nose, mouth are showed no secretion.After modeling, 16 mouse survive, but during experiment in 24 days, and two groups
Mouse is 3 dead, therefore survival rate is 67.5%, and Chinese medicine group is suitable with negative group.
2) weight of each group mouse and the change situation of spleen index, in treatment end, without obvious between two groups of mouse weight
Difference, Chinese medicine group spleen weight is larger, but the equal > 0.05 of p value, is specifically relatively shown in Table 2.
The case where when 2 each group mouse treatment end of table, compares (n=5)
| Group | Weight (g) | Spleen weight (g) | Spleen index |
| Negative control group (physiological saline) | 16.26±0.82 | 0.069±0.0195 | 0.004±0.0011 |
| Chinese medicine compound prescription group | 17.52±2.04 | 0.092±0.0237 | 0.005±0.0011 |
| P value (organizes ratio with feminine gender) | 0.253 | 0.137 | 0.209 |
3) influence of the Chinese medicine compound prescription to melanoma Lung metastases:
The comparison (n=5) of Pulmonary metastasis focuses size and quantity when 3 each group mouse treatment end of table
| Group | ≤1mm | 1~3mm | ≥3mm |
| Negative control group (physiological saline) | 9.0±5.6 | 14.4±5.4 | 14.4±3.8 |
| Chinese medicine compound prescription group | 15.6±3.6 | 7.8±4.3 | 3.8±2.0 |
| P value (organizes ratio with feminine gender) | 0.063 | 0.067 | 0.001 |
At the end of experiment, in the Pulmonary metastasis focuses of Chinese medicine intervention group, diameter≤1mm number is more than negative group, but diameter is 1
The transfer stove number of~3mm and >=3mm are that Chinese medicine group is less than negative group, especially >=3mm group, and p value has less than 0.05
Statistical significance prompts it to can be reduced the Lung metastases of melanoma.
4) influence of the Chinese medicine compound prescription to mouse immune cell content:
Influence of 4 Chinese herbs group of table to mouse peripheral blood immunocyte content
*: the content of macrophage is using all lymphocytes as denominator, with CD45 and F4/80 cell positive simultaneously
It is obtained for molecular computing.The content of #:NK cell be using all lymphocytes as denominator, it is positive simultaneously with CD45 and NK1.1
Cell obtains for molecular computing.
Influence of 5 Chinese herbs group of table to mouse spleen immunocyte content
*: the content of macrophage is using all lymphocytes as denominator, with CD45 and F4/80 cell positive simultaneously
It is obtained for molecular computing.The content of #:NK cell be using all lymphocytes as denominator, it is positive simultaneously with CD45 and NK1.1
Cell obtains for molecular computing.
At the end of experiment, we have detected the content of various immunocytes in the peripheral blood and spleen of mouse, compare Chinese medicine
Their change situation after intervention.The experimental results showed that (table 4 and table 5), either T cell, NK cell or macrophage,
It is not all decreased obviously (p < 0.05) after content medicine in use, illustrates the use of the Chinese medicine, the immunity to body is that do not have
The effect of weakening.
The experimental results showed that (Fig. 1), in animal integral experiment, the lung of negative control group almost all black is said
There is tumour cell in bright most lung tissue, and the lung of Chinese medicine compound prescription group animal still has the lung tissue of white.Pass through
Count the number of different size of transfer stove, it is seen that can be reduced Lung metastases after Chinese medicine intervention, illustrate that the herbal mixture is inhibiting black
Effect is obvious in terms of melanoma Lung metastases.
From the above experiment as can be seen that this Chinese medicine compound prescription can on the basis of not reducing all kinds of immunocyte contents of body,
It is played the effect of inhibiting in terms of melanoma Lung metastases, embodies the effect unique of the Chinese medicine compound prescription.
Claims (8)
1. a kind of compound traditional Chinese medicine composite inhibits the application in cutaneous melanoma Lung metastases drug in preparation,
Wherein, the compound traditional Chinese medicine composite is grouped as by the group of following parts by weight: 15~30 parts of astragalus root, frying Radix Codonopsis 15
~30 parts, 10~20 parts of rhizoma atractylodis macrocephalae, 15~30 parts of Poria cocos, 15~30 parts of Chinese yam, 5~10 parts of radix glycyrrhizae preparata, 10~20 parts of dark plum are processed,
10~20 parts of trigone, 10~20 parts of curcuma zedoary, 15~30 parts of hairyvein agrimony, 15~30 parts of field pennycress.
2. application according to claim 1, which is characterized in that the compound traditional Chinese medicine composite is by following parts by weight
Group is grouped as:
15~20 parts of astragalus root, 15~20 parts of Radix Codonopsis are fried, 10~15 parts of rhizoma atractylodis macrocephalae, 15~20 parts of Poria cocos, 15~30 parts of Chinese yam, is processed
5~10 parts of Radix Glycyrrhizae, 10~15 parts of dark plum of toast, 10~15 parts of trigone, 10~15 parts of curcuma zedoary, 20~30 parts of hairyvein agrimony, field pennycress 20
~30 parts.
3. application according to claim 1, which is characterized in that the compound traditional Chinese medicine composite, dosage form are decoction, sugar
Starch agent, mixture, granule, tablet or capsule.
4. application according to claim 1, which is characterized in that the compound traditional Chinese medicine composite is prepared as follows
It arrives: by the Chinese medicine astragalus root of formula ratio, frying Radix Codonopsis, rhizoma atractylodis macrocephalae, Poria cocos, Chinese yam, radix glycyrrhizae preparata, toast dark plum, trigone, curcuma zedoary, celestial being
Crane grass and field pennycress add water to cook to obtain the final product.
5. application according to claim 4, which is characterized in that decoct every time, the weight of the water of addition is Chinese medicine gross weight
5~20 times of amount；The number of decoction is 1~3 time, and each decocting time is 1~3 hour.
6. application according to claim 4 or 5, which is characterized in that after adding water to cook, decocting liquid is concentrated to obtain the final product.
7. application according to claim 6, which is characterized in that be added or be added without sucrose into concentrate, sterilizing is made
At syrup or decoction；Or, dextrin, Steviosin are added into concentrate, tablet, capsule or granule is made.
8. application according to claim 1 or claim 7, which is characterized in that the compound traditional Chinese medicine composite passes through strengthening vital QI to eliminate pathogenic factors
To reduce the Lung metastases degree of melanoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710029836.8A CN106511915B (en) | 2017-01-16 | 2017-01-16 | A kind of compound traditional Chinese medicine composite is inhibiting the application in cutaneous melanoma Lung metastases drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710029836.8A CN106511915B (en) | 2017-01-16 | 2017-01-16 | A kind of compound traditional Chinese medicine composite is inhibiting the application in cutaneous melanoma Lung metastases drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106511915A CN106511915A (en) | 2017-03-22 |
| CN106511915B true CN106511915B (en) | 2019-06-21 |
Family
ID=58335481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710029836.8A Active CN106511915B (en) | 2017-01-16 | 2017-01-16 | A kind of compound traditional Chinese medicine composite is inhibiting the application in cutaneous melanoma Lung metastases drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511915B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200397847A1 (en) * | 2019-06-18 | 2020-12-24 | St. Lotus Biotech Corp. | Herbal composition for inhibiting melanoma cell metastasis and manufacturing method thereof |
| TWI701037B (en) * | 2019-06-18 | 2020-08-11 | 聖蓮生物科技股份有限公司 | An herbal composition for inhibiting melanoma cell metastasis and manufacturing method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103494915B (en) * | 2013-09-30 | 2015-06-10 | 侯俊光 | Preparation method and application of breast lump dissipating tablet |
-
2017
- 2017-01-16 CN CN201710029836.8A patent/CN106511915B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106511915A (en) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106390013B (en) | It is a kind of inhibit colorectal cancer hepatic metastases compound traditional Chinese medicine composite preparation method and application | |
| CN103520577A (en) | Medicine-and-food dual-purpose preparation for treating pneumoconiosis, clearing away lung-heat and nourishing heart and preparation method for medicine-and-food dual-purpose preparation | |
| CN101884772B (en) | Food therapy preparation for preventing and treating gastropathy based on theories of preventive treatment of disease and medicine food homology | |
| CN102526478A (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| WO2022143466A1 (en) | Medicinal and edible plant-based traditional chinese medicine composition for preventing cancers | |
| CN108713746A (en) | A kind of integration of drinking and medicinal herbs composition and its preparation method and application | |
| CN101716318A (en) | Traditional Chinese medicine preparation for treating tumor of digestive system | |
| CN107468747A (en) | A kind of ginseng composition for being advantageous to anticancer, anti-cancer and preparation method thereof | |
| CN106511915B (en) | A kind of compound traditional Chinese medicine composite is inhibiting the application in cutaneous melanoma Lung metastases drug | |
| CN103181560B (en) | Health food having effects of life cultivation and health preservation in winter and preparation method thereof | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN101708306B (en) | Chinese medicinal composition for treating gastropathy and preparation method thereof | |
| CN105596994A (en) | Medicine for treating lung cancer cell proliferation | |
| CN105999096A (en) | Composition for enhancing immunity and application | |
| CN114224998B (en) | Traditional Chinese medicine composition, preparation and application for treating spleen-kidney yang deficiency type functional dyspepsia | |
| CN106421665B (en) | A kind of compound traditional Chinese medicine composite improves the immunity of the human body the application in drug in preparation | |
| CN104825817B (en) | A kind of Chinese medicine preparation with antitumor action | |
| CN108310156A (en) | A kind of Chinese medicine composition and preparation method thereof for treating paediatrics diarrhea | |
| CN100562325C (en) | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof | |
| CN113769029A (en) | Medicinal and edible herbal composition for improving intestinal absorption and immune function | |
| CN103169072A (en) | Ginseng composition, and preparation method and use thereof | |
| CN102895445A (en) | Traditional Chinese medicine for treating dysentery | |
| CN106376930A (en) | Nutritional medicinal diet powder for treating chronic diarrhoea and preparation method thereof | |
| CN112914009A (en) | Health-care solid beverage for yang-deficiency constitution and preparation method thereof | |
| CN110025011A (en) | A kind of Radix Ophiopogonis ginseng lozenge of strengthen immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |